JSS Sustainable Equity - Future Health C CHF acc

Reference Data

ISIN LU2041626032
Valor Number 49473298
Bloomberg Global ID
Fund Name JSS Sustainable Equity - Future Health C CHF acc
Fund Provider J. Safra Sarasin Investmentfonds AG Basel, Switzerland
Phone: +41 58 317 44 44
Web: www.jsafrasarasin.com
Fund Provider J. Safra Sarasin Investmentfonds AG
Representative in Switzerland J. Safra Sarasin Investmentfonds AG
Basel
Phone: +41 58 317 44 00
Distributor(s) Bank J. Safra Sarasin AG
Basel
Phone: +41 58 317 44 00
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund management company and/or distributor charges an issuing commission (different commissions can be charged for the same fund depending on the sales channel)
Redemption Condition The fund does not charge any redemption commission and/or fees (units are redeemed at the NAV)
Investment Strategy *** The investment objective of the fund is to achieve long-term capital growth. The Reference Currency of the Sub-Fund is the US Dollar (USD).
Peculiarities

Fund Prices

Current Price * 101.34 CHF 12.11.2024
Previous Price * 102.14 CHF 08.11.2024
52 Week High * 108.80 CHF 16.07.2024
52 Week Low * 87.97 CHF 15.11.2023
NAV * 101.34 CHF 12.11.2024
Issue Price *
Redemption Price *
Closing Price *
Indicative Minimum Price
Fund Assets *** 130,220,626
Unit/Share Assets *** 16,006,231
Trading Information SIX

Performance

YTD Performance +10.81% 29.12.2023
12.11.2024
1 month -1.62% 15.10.2024
12.11.2024
3 months -1.37% 12.08.2024
12.11.2024
6 months -1.68% 13.05.2024
12.11.2024
1 year +15.74% 13.11.2023
12.11.2024
2 years -6.03% 14.11.2022
12.11.2024
3 years -21.61% 12.11.2021
12.11.2024
5 years +1.34% 21.11.2019
12.11.2024

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Eli Lilly and Co 8.43%
Danaher Corp 5.66%
Boston Scientific Corp 5.07%
Sanofi SA 4.97%
Novo Nordisk AS Class B 4.31%
Pfizer Inc 3.77%
Zoetis Inc Class A 3.67%
Biomarin Pharmaceutical Inc 3.54%
Gilead Sciences Inc 3.51%
Merck & Co Inc 3.50%
Last data update 30.09.2024

Cost / Risk

TER 1.37%
TER date 30.04.2024
Performance Fee ***
PTR
Max. Management Fee *** 1.50%
Ongoing Charges *** 1.32%
SRRI ***
SRRI date *** 31.10.2024

ESG Fund Ratings

Low Carbon Designation ***
ESG Rating Overall ***
ESG Rating Corporate ***
ESG Rating Sovereign ***
% AuM H&S Controversies ***

Breakdowns

Countries ***

Stock Sectors ***

Bond Sectors ***

ESG Carbon Metrics

Avg Carbon Risk Score ***
Avg Carbon Risk Cat Avg ***
% AuM Covered Carbon ***
Avg Fossil Fuel Exposure ***
Fossil Fuel Cat Avg ***

ESG Strategy

Strategy Level 1 ***
Strategy Level 2 ***
Strategy Level 3 ***
Exclusions Level 1 ***
Exclusions Level 2 *** GMOs

* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)